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Abstract
The nuclear receptor peroxisome proliferator-activated receptor g (PPARg) is a key transcriptional regulator of both lipid
metabolism and inﬂammation. The importance of PPARg is accentuated by the widespread use of synthetic PPARg
agonists, thiazolidinediones (such as rosiglitazone), as drugs for insulin resistance and type II diabetes. Fractalkine
(FKN) and FKN receptor (FR) play an important role in the immune responses by regulating leukocyte migration and
adhesion to inﬂamed peripheral tissues. In this study, we have identiﬁed a novel link between PPARg activation and FKN
signaling. On one hand, the activation of PPARg by rosiglitazone in macrophages not only represses the transcription of
the FR gene, but also prevents the plasma membrane translocation of the FR protein. On the other hand, the activation of
PPARg by rosiglitazone in endothelial cells also impedes the nuclear export of FKN. Together, these data suggest that
PPARg activation represses FKN signaling. These ﬁndings indicate a previously unrecognized mechanism that may
contribute to the anti-inﬂammatory effect of PPARg.
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Introduction
The migration of leukocytes into inﬂamed peripheral
tissues and lymphoid organs involves a cascade of
molecular events ﬁnely regulated by chemokines and
cell adhesion molecules. Fractalkine (FKN), also known
as CX3CL1, is a structurally unique chemokine that can
act either as a soluble chemotactic factor or as a
membrane-anchored adhesion molecule for circulating
leukocytes. It is expressed on endothelial cells, smooth
muscle cells, and neurons that are activated by pro-
inﬂammatory cytokines. The FKN receptor (FR), also
known as CX3CR1, is expressed on monocytes and
mature macrophages, natural killer cells, cytotoxic
effector T cells, and mucosal dendritic cells, all of
which play important roles in the inﬂammatory and
immune responses.
Accumulating evidence in both clinical studies and
animal disease models has shown that FKN signaling is
also involved in the pathogenesis of various chronic
inﬂammatory diseases, such as atherosclerosis (Lesnik
et al. 2003), age-related macular degeneration (AMD;
Combadiere et al. 2007), and rheumatoid arthritis
(Nanki et al. 2004). Abrogation of FKN signaling by
FR deletion in mice results in reduced accumulation of
tissue-speciﬁc macrophages, such as foam cells at
atherogeniclesionsandmicroglialcellsatsitesofretinal
degeneration. In addition, polymorphisms in human
FR, which reduce its binding activity to FKN, have been
reported to increase the risk of AIDS and to reduce the
risk of coronary artery disease (Faure et al. 2000, Moatti
et al. 2001). Therefore, the FKN signaling represents a
newtargetfor thetreatment of anarrayof inﬂammatory
and immune disorders.
Peroxisome proliferator-activated receptor g
(PPARg) is a member of the nuclear hormone receptor
superfamily of ligand-responsive transcription factors
(Evans et al. 2004). It forms a functional heterodimer
with the retinoid receptor (RXR)a. Certain lipophilic
compounds have been identiﬁed as PPARg ligands that
can bind to the receptor complex and stimulate its
transcriptional activity. Naturally occurring PPARg
ligands include native and oxidized polyunsaturated
fatty acids and arachidonic acid derivatives such as
prostaglandins and eicosanoids. Synthetic PPARg
ligands include thiazolidinediones (TZDs) such as
rosiglitazone (BRL; Willson & Wahli 1997). PPARg
regulates a diverse array of physiological processes
including adipogenesis, lipid metabolism, and insulin
sensitivity, as well as diseases such as obesity, diabetes,
and atherosclerosis. The importance of this receptor is
accentuated by the widespread use of TZDs as drugs for
insulin resistance and type II diabetes.
Numerous studies using mouse genetic models or
synthetic PPARg agonists have suggested that PPARg
also regulates both native and acquired immune
responses (Bensinger & Tontonoz 2008). For example,
we have recently reported an unexpected yet important
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inﬂammatory milk lipids in the lactating mammary
glands, using a mouse model in which PPARg is
speciﬁcally deleted in the hematopoietic and endo-
thelial cells. The ingestion of this ‘toxic’ milk by nursing
neonates results in growth retardation and inﬂam-
matory alopecia (Wan et al. 2007). Furthermore,
conditional deletion of PPARg in macrophages and
intestinal epithelial cells demonstrated that it is
important in the regulation of inﬂammatory bowel
disease (Adachi et al. 2006, Shah et al. 2007).
Surprisingly, macrophage-speciﬁc deletion of PPARg
was shown to regulate diet-induced obesity and
insulin sensitivity, which are the key components
of type II diabetes and metabolic syndrome (Odegaard
et al. 2007).
To further understand how PPARg regulates the
immune system, we have found that PPARg activation
by rosiglitazone suppresses the FKN signaling via
multiple mechanisms. In macrophages, rosiglitazone
suppresses both the expression and the membrane
translocation of FR. In endothelial cells, rosiglitazone
prevents the nuclear export of FKN. Taken together,
this evidence provides a previously unrecognized
mechanism that may contribute to the anti-inﬂam-
matory effect of PPARg.
Materials and methods
Macrophage cell culture
For bone marrow-derived macrophages (BMDMs),
mouse bone marrow was ﬂushed from the femur
and tibia with serum-free DMEM (Invitrogen). After
passing through a 40 mm cell strainer, the cells were
cultured in macrophage differentiation medium
(DMEM containing 20% fetal bovine serum (FBS)
and 30% L929 cell-conditioned medium) for 8 days.
Differentiated macrophages were replated in RPMI
medium containing 10% FBS for various experiments.
Peritoneal macrophages were isolated 3 days after
thioglycollate challenge and were cultured in RPMI
medium containing 10% FBS. The human monocyte
cell line THP-1 and the mouse macrophage cell line
RAW264.7 were purchased from the American Type
Culture Collection (Manassas, VA, USA). Cells were
treated with the indicated stimulant in the presence or
absence of a ligand before harvesting. BRL was
purchased from Cayman Chemical Ann Arbor, Michigan,
USA; GW501516 and LG268 were synthesized; TPA
(12-0-tetradecanoylphorbol 13-acetate) was obtained from
Sigma; andtumornecrosisfactor-a(TNFa)wasobtained
from BD Biosciences (San Jose, CA, USA). Concen-
trations used were BRL, 1 mM; GW501516, 0.1 mM;
LG268, 0.1 mM; TPA, 40 ng/ml; and TNFa, 10 ng/ml.
Embryonic stem cell macrophage differentiation
Embryonic stem (ES) cells were trypsinized and
depleted of feeder cells by culturing in IMDM
(Invitrogen) supplemented with 5% FCS for 3–4 h.
Nonadherent ES cells were seeded in 0.9% methylcel-
lulose in IMDM supplemented with 15% FCS, transfer-
rin (300 mg/ml, Roche), PFHM-II (5%, Invitrogen),
ascorbic acid (50 mg/ml), and monothioglycerol
(4!0
K4 M). Embryoid bodies were collected on day
6, trypsinized, and replated in IMDM supplemented
with 15% L929 cell-conditioned medium and mIL-3
(1 ng/ml, BD Biosciences Pharmingen). Two days later,
macrophage precursors that developed as nonadherent
cells were collected and cultured in IMDM supple-
mented with 15% L929 cell-conditioned medium.
Adherent macrophages developed over the next 4 to
5 days, and were used for the experiments starting on
day 5 (Keller et al. 1993, Chawla et al. 2001a).
Transient transfection and reporter analyses
A luciferase reporter was co-transfected into the murine
macrophage cell line RAW264.7 cells with expression
plasmids for b-gal, PPARg1, and RXRa using Lipofecta-
mine 2000 (Invitrogen). Next day, the cells were treated
with 1 mM BRL or DMSO vehicle control for 20–24 h.
Luciferase activity was normalized by b-gal. Aox–PPRE–
luc was a positive control. The hFR promoter–luciferase
constructs P1, P2, and P3 were generously provided by
Dr Combadiere’s Laboratory (Garin et al. 2002). The
P2-3 kb–luciferase plasmid was constructed by PCR
cloning of the upstream genomic DNA sequence into
the pGL3-Basic vector (Promega).
RNA extraction, real-time quantitative PCR and
northern blot
RNA was extracted using TRIZOL (Invitrogen) accord-
ing to the manufacturer’s protocol. For real-time
quantitative PCR (RT-QPCR) analysis, RNA was ﬁrst
treated with RNase-free DNaseI using the DNA-free kit
(Ambion, TX, USA) to remove all genomic DNA. Then
the RNA was reverse transcribed into the ﬁrst-strand
cDNA using the Superscript First-Strand Synthesis System
(Invitrogen). A negative control experiment without
reverse transcriptase was performed for all samples to
exclude genomic DNAcontamination. RT-QPCR (SYBR
Green) analyses of the cDNA were performed using an
Applied Biosystems 7700 Sequence Detection System.
Primer sequences for mouse FR were 50-ATCAGCATC-
GACCGGTACCT-30 (forward) and 50-GTGACACCGTGCTG-
CACTGT-30 (reverse). Each reaction was performed in
triplicate or quadruplicate in a 384-well format. The
expression of each gene was normalized to L19
expression. For the northern blot analysis, total RNA
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t r a n s f e r r e dt oH y b o n dN C nylon membrane
(Amersham Pharmacia Biotech). cDNA probes were
isolated from IMAGE clones and were labeled with a
High Prime kit (Roche) and hybridized with the
membrane at 42 8C overnight. After washing, the blot
wasexposedtoaﬁlmandquantiﬁedbyPhosphorImager.
Immunoﬂuorescence staining
The cells were ﬁxed in 2% paraformaldehyde at 4 8C for
30 min, washed, and stained with rabbit anti-hFR or
rabbit anti-hFKN primary antibodies (Torrey Pines
Biolabs, East Orange, NJ, USA) at 1:200 for 1 h
(Hosokawa et al. 2005, Jamieson et al. 2008). Following
two washes, the cells were stained with FITC-conjugated
goat anti-rabbit IgG secondary antibody (Jackson
ImmunoResearch Laboratories, West Grove, Pennsylvania,
USA) at 1:1000 for 1 h. After two washes, cover slips
were mounted with the Vectashield medium
containing DAPI (Vector Laboratories Burlingame,
CA, USA). Negative control experiments using a
nonimmune IgG primary antibody, or a secondary
antibody alone without a primary antibody, were
performed under the same staining condition to
exclude any background signal.
Flow cytometry
Macrophages were cultured in petri dishes and were
then detached for ﬂuorescence-activated cell sorting
(FACS) analysis with ice-cold PBS containing 5 mM
EDTA. All samples were blocked with mouse IgG for
15 min and were then incubated for 15 min at 4 8C with
FITC-conjugated antibodies F4/80 (Serotec, Raleigh,
NC, USA) or CD11b (Mac-1) (BD Pharmingen, San
Diego, CA, USA). Propidium iodide was used for live
cell gating. Samples were analyzed on the Becton–
Dickinson FACScan using CellQuest software. A
negative control experiment using a FITC-conjugated
nonimmune IgG was performed under the same
condition to determine the baseline.
Results
Rosiglitazone activation of PPARg down-regulates FR
in macrophages
We investigated the effect of PPARg activation by
rosiglitazone on cytokine expression in the THP-1
human monocyte cell line and the TPA-differentiated
THP-1macrophages.TheRNAexpressionof FRinTPA-
differentiated THP-1 macrophages was inhibited by
BRL in a time-dependent manner (Fig. 1A and B). After
24-htreatment,BRLreducedtheFRexpressionby84%.
As a positive control, BRL induced the expression of
LXRs by 2.2-fold as reported previously (Chawla et al.
2001b). In contrast, the PPARd agonist GW501516 did
not induce LXRs expression, but suppressed FR
expression (49%). In addition, the expression of
CD44, another cell adhesion receptor for hyaluronic
acid, was not signiﬁcantly affected by BRL or GW501516
treatment. Furthermore, the TPA-induced PPARg
expression was also suppressed by 29% after 24-h
treatment of BRL, but not by GW501516 treatment.
Interestingly, the suppression of FR expression by BRL
occurred only in the THP-1 macrophages but not in the
THP-1 monocyte precursors in the absence of TPA-
induced macrophage differentiation (Fig. 1C).
We next examined the effect of PPARg activation by
BRL on FR expression in primary macrophages that
were differentiated ex vivo. First, mouse bone marrow
cells were differentiated into macrophages (BMDMs),
and treated with BRL, GW501516, LG268 (an RXRa
agonist), or vehicle control for 24 h. Both BRL and
LG268, but not GW501516, suppressed FR expression
(Fig. 1D). Secondly, mouse peritoneal macrophages
were elicited with thioglycollate and were cultured in
the presence of each ligand or vehicle control for 24 h.
Consistently, FR expression was inhibited by both BRL
and LG268, while GW501516 had much less suppressive
effect (Fig. 1E). These results suggested that the
activation of the PPARg–RXRa receptor complex by
their agonists, BRL and LG268, results in the down-
regulation of the transcription of the gene encoding
the FR in both human and murine macrophages.
Rosiglitazone-activated PPARg suppresses the
upstream FR promoter
To test if PPARg directly regulates the promoter for the
FR gene, we performed transient transfection and
reporter analysis in the murine macrophage cell line
RAW264.7 cells. The promoter and upstream genomic
DNA region for the human FR gene has been
sequenced and characterized (Garin et al. 2002).
Expression vectors for PPARg and RXRa were co-trans-
fected with a luciferase reporter driven by an FR
promoter. First, we tested the three proximal promoter
regions described by Garin et al. (P1, P2, and P3). As
shown in Fig. 2A, these promoter fragments were not
regulated by BRL treatment. To test the upstream
promoter region, we cloned a 3 kb genomic DNA
fragment into the luciferase reporter construct
(P2-3 kb). Luciferase expression from this larger
promoter was suppressed by BRL by 47%, suggesting
that the PPARg–RXRa receptor complex functions
through the upstream FR promoter region to exert the
inhibition of its transcription. As a positive control,
luciferase expression from the PPRE identiﬁed in the
acyl-CoA oxidase promoter (Aox–PPRE) was induced
by BRL by 8-fold (Fig. 2B).
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of RNA expression in TPA-differentiated THP-1 macrophages. THP-1 cells were differentiated with TPA
(40 ng/ml) for 48 h before being treated with rosiglitazone (BRL, 1 mM) or GW501516 (GW, 0.1 mM) for the
indicated amount of time. RNA was isolated and analyzed by northern blot using gene-speciﬁc probes.
(B) Quantiﬁcation of the northern blot analyses of FR and LXR in 1A with PhosphorImager. The expression
ofFRandLXRwasnormalizedbytheexpression ofGADPH. (C)NorthernblotanalysesofRNAexpression
in undifferentiated THP-1 monocytes. THP-1 cells were treated with rosiglitazone (BRL, 1 mM) or
GW501516 (GW, 0.1 mM) for the indicated amount of time in the absence of TPA. RNA was isolated and
analyzed by northern blot using gene-speciﬁc probes. (D and E) RNA expression analysis of FR in bone
marrow-derived macrophages (BMDMs) (D) and thioglycollate-elicited peritoneal macrophages (E).
Primary mouse macrophages were treated with rosiglitazone (BRL, 1 mM), GW501516 (GW, 0.1 mM), or
LG100268 (LG268, 0.1 mM) for 24 h. RNA was isolated and analyzed by RT-QPCR. FR expression was
normalized by the expression of the ribosomal protein gene L19. All experiments were repeated at least
three times, and representative results are shown. *Indicates P!0.05; **indicates P!0.01.
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PPARg dependent
We next examined whether the inhibitory effect of BRL
on FR expression was PPARg dependent or PPARg
independent. Since the complete deletion of PPARg in
mice results in embryonic lethality (Barak et al. 1999),
we differentiated macrophages from PPARgK/K or
wild-type ES cells as described previously (Fig. 3A;
Chawla et al. 2001a). As shown in Fig. 3B, ES cells were
efﬁciently differentiated into macrophages, evidenced
by the expression of macrophage cell surface markers
F4/80 and CD11b by FACS analysis. Both northern blot
(Fig. 3C) and RT-QPCR analyses (Fig. 3D) demon-
strated that BRL inhibited FR expression only in the
wild-type macrophages but not in the PPARgK/K
macrophages. This indicates that the suppression of FR
transcription by BRL is a PPARg-dependent effect,
rather than a receptor-independent effect.
Rosiglitazone activation of PPARg disrupts the
membrane translocation of FR in macrophages
The function of the FR requires its plasma membrane
translocationforligandbindingandsignaltransduction.
We next examined whether BRL activation of PPARg
alteredthe subcellular localization of FR. Immunoﬂuor-
escent staining using an antibody against the human FR
demonstrated that BRL treatment reduced not only the
receptorexpressionbutalsoitsmembraneassociationin
THP-1macrophages(Fig.4).Inthevehicle-treatedcells,
the majority of the receptors were at the plasma
membrane, demonstrated by the bright ring at the cell
junctions. In contrast, in the BRL-treated cells, this
brightringwasabsent,andmostofthereceptorsresided
in the cytoplasm and the nucleus. This result suggests
thatBRL-activatedPPARg employs asecondmechanism
to inhibit FR function in macrophages by hampering its
plasma membrane translocation.
Rosiglitazone activation of PPARg prevents FKN
nuclear export in endothelial cells
The migration and adhesion of macrophages that
express FR also depend on the FKN ligand expressed
on the cells in the inﬂamed tissues, such as endothelial
cells. We next examined if BRL treatment regulates the
expression and subcellular localization of FKN in the
human endothelial cell line HUVEC. First, we measured
theRNA expressionof FKNusingnorthernblotanalysis.
FKN was dramatically induced by TNFa by 48-fold, while
it was down-regulated by TPA by 76% (Fig. 5A). LG268
treatment for 24 h suppressed the TNFa-induced FKN
expression by 30%. In contrast, neither BRL nor
GW501516hadaneffectontheFKNexpression(Fig.5A).
Figure 2 Rosiglitazone-activated PPARg suppresses
the upstream FR promoter. (A) Transient transfection analysis
of the human FR promoter-driven luciferase reporters in the
RAW264.7 cells. Cells were transfected with plasmids for
receptors and reporters for 20–24 h before being treated with BRL
(1 mM) or vehicle control. Reporter activity assays were performed
20–24 h later. Luciferase activity was normalized to an internal
b-galactosidase control.ThepositionofthegenomicDNAfragment
relative to the transcriptional start site in each promoter construct is
shown in parentheses. (B) Transient transfection analysis of the
acyl-CoA oxidase (Aox)–PPRE-driven luciferase reporter as a
positive control for BRL-mediated PPARg activation. For all
experiments, nZ3; *indicates P!0.05; **indicates P!0.01.
Figure 3 Rosiglitazone suppression of FR expression is
PPARg dependent. (A) A schematic diagram for the macrophage
differentiation from embryonic stem cells. ES, embryonic stem
cell; EB, embryoid body; MeC, methylcellulose; L-CM,
L-conditioned medium; Mf, macrophage. (B) Flow cytometry
analysis of the ES-derived macrophages with FITC-conjugated
antibodies for macrophage cell surface markers (F4/80 or CD11b,
light color histogram in the front layer) or FITC-conjugated
nonimmune IgG isotype control (dark color histogram in the back
layer). The histogram for CD11b (left) or F4/80 (right) is overlaid
on the histogram for the nonimmune IgG isotype control.
The percentage of the cells positive for each macrophage marker
relative to the isotype control is illustrated. (C and D) Northern blot
(C) and RT-QPCR (D) analyses of RNA expression in wild-type or
PPARgK/K macrophages treated with BRL or vehicle control for
24 h. In the northen blot analysis (C), BRL suppressed FR
expression (normalized by GAPDH) by 81% in the wild-type
macrophages, while increased FR expression (normalized by
GAPDH) by 12% in the PPARgK/K macrophages. For all the
experiments, nZ3; **indicates P!0.01.
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antibody against the human FKN demonstrated that
BRL treatment did alter its subcellular localization in
HUVECs (Fig. 5B). In the vehicle-treated cells, FKN was
concentrated more in the cytoplasm than in the
nucleus. In contrast, in the BRL-treated cells, FKN was
mainly localized in the nucleus. This result suggests that
BRL activation of PPARg may dampen the FKN/FR
signaling by impeding FKN nuclear export.
Discussion
In this study, we have identiﬁed a novel link between
PPARg and the FKN/FR signaling. On one hand, the
activation of PPARg by rosiglitazone in macrophages
not only represses the transcription of the FR gene,
but also prevents the plasma membrane translocation
of FR protein. On the other hand, the activation
of PPARg by rosiglitazone in endothelial cells also
impedes the nuclear export of FKN. Together,
these ﬁndings indicate a previously unrecognized
mechanism that may contribute to the anti-inﬂam-
matory effect of PPARg.
We have found that BRL-activated PPARg acts
through an upstream promoter region to suppress
the transcription of the FR gene in macrophages.
A recent study proposed a model for the molecular
events that underlie PPARg-mediated transrepression
of inﬂammatory genes in macrophages (Pascual et al.
2005). Activation of PPARg inhibits inﬂammatory gene
expression by preventing the inﬂammatory signal-
speciﬁc removal of the co-repressor complex. In future
study, it would be interesting to test whether PPARg
regulates the FR promoter via this transrepression
mechanism.
Our data have demonstrated that BRL-activated
PPARg also prevents FR plasma membrane transloca-
tion, which is pivotal for its function as a chemo-
attractant and adhesion molecule. Human genetic
studies identiﬁed ﬁve SNPs in the FR coding sequence,
all of which were in the transmembrane domains of the
receptor (Faure et al. 2000). Two of the mutations
(V249I and T280M) were associated with increased
susceptibility to HIV infection and accelerated pro-
gression to AIDS, as well as reduced risk of acute
coronary events, potentially due to a signiﬁcant
decrease in the number of FKN-binding sites per cell
(Moatti et al. 2001). T280M homozygosity was also
found to be more frequent in AMD patients, which
is likely due to impaired monocyte chemotaxis
(Combadiere et al. 2007). Furthermore, the T280M
mutation was independently associated with a lower risk
of cardiovascular disease, possibly as the result of
reduced cell–cell adhesion under physiological shear
conditions (McDermott et al. 2003). Collectively, these
studies demonstrated that the FR transmembrane
domain is critical for the FKN-mediated chemotaxis
and cell adhesion. Our ﬁnding that PPARg activation
can disrupt FR membrane association in macrophages
Figure 4 Rosiglitazone activation of PPARg disrupts the
membrane translocation of FR in macrophages. TPA-differen-
tiated THP-1 macrophages were treated with BRL or DMSO
control for 24 h and stained with a rabbit anti-hFR primary
antibody followed by a FITC-conjugated goat anti-rabbit IgG
secondary antibody. The nuclei were counterstained with DAPI.
Negativecontrolexperiments wereperformedusing a nonimmune
IgG primary antibody, or a secondary antibody alone without a
primary antibody, and no background signal was detected (blank
images not shown). All experiments were repeated at least three
times, and representative results are shown.
Figure 5 Rosiglitazone activation of PPARg prevents FKN
nuclear export in endothelial cells. (A) Northern blot analysis of
RNA expression in HUVECs. The cells were treated with TPA
(40 ng/ml) or TNFa (10 ng/ml) for 24 h in the presence of DMSO
vehicle control, BRL (1 mM), GW501516 (0.1 mM), or LG100268
(0.1 mM). (B) Immunoﬂuorescence analysis of the subcellular
localizationofFKNin HUVECs.Thecellsweretreatedwith BRLor
DMSOcontrolfor24 h andstained witha rabbit anti-hFKNprimary
antibody followed by a FITC-conjugated goat anti-rabbit IgG
secondary antibody. The nuclei were counterstained with DAPI.
Negativecontrolexperiments wereperformedusing a nonimmune
IgG primary antibody, or a secondary antibody alone without a
primary antibody, and no background signal was detected (blank
images not shown). All experiments were repeated at least three
times, and representative results are shown.
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which PPARg inhibits FR function.
We have shown that although BRL-activated PPARg
does not affect FKN expression, it does alter FKN
subcellular localization. BRL treatment prevents the
nuclear export of FKN, resulting in its nuclear
accumulation. This suggests that PPARg activation can
impede the FKN/FR signaling by an additional
mechanism in the endothelial cells where it decreases
the membrane association and/or secretion of FKN,
thus reducing leukocyte migration and adhesion. In
addition, the RXRa agonist LG100268, but not BRL or
GW501516, down-regulated the TNFa-induced FKN
expression in HUVECs by 30%, suggesting that it may
dimerize and activate a nuclear receptor other than
PPARg and PPARd to inhibit FKN transcription.
Emerging evidence reveals that PPARg is a key
regulator of both lipid metabolism and inﬂammation.
The ability to integrate metabolic signaling and
inﬂammatory signaling makes PPARg an attractive
target for intervention in human metabolic diseases
and immune disorders. Recent studies demonstrated
that the FKN/FR signaling plays an important role in
leukocyte migration and adhesion to inﬂammatory
sites, thereby regulating disease processes such as
atherosclerosis. Our study revealed a novel link between
PPARg activation and FKN/FR signaling, providing a
potential mechanism underlying the anti-inﬂammatory
role of PPARg. These ﬁndings may enhance our
understanding of the effect of the diabetic drug
rosiglitazone on diseases including atherosclerosis,
type II diabetes, AIDS, and AMD.
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